EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

13 September 2019
EMA/CVMP/450607/2019
Committee for Medicinal Products for Veterinary Use

Summary of opinion[1] (post-authorisation)

Vectra Felis

International non-proprietary name (INN): dinotefuran / pyriproxyfen

On 12 September 2019, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion[2], recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Vectra Felis. The marketing authorisation holder for this veterinary medicinal product is CEVA Santé Animale.

Vectra Felis is currently authorised as spot-on solution for the treatment and prevention of flea infestations in cats. The variation concerns the change of legal status from prescription-only to non-prescription veterinary medicine.

Detailed conditions for the use of this product are described in the updated summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

[1] Summaries of opinion are published without prejudice to the Commission Decision.
[2] Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union